Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Naoyuki Nogami, Delvys Rodríguez‐Abreu et al.|The Lancet Respiratory Medicine|2019Cited by 937
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung CancerJoachim von Pawel, Markus F. Renschler, Robert M. Jotte et al.|Journal of Clinical Oncology|2014Cited by 344
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or ChemotherapyKai He, Ticiana Leal, David Berz et al.|Journal of Thoracic Oncology|2023Cited by 38
P2.01-013 Nab-Paclitaxel/Carboplatin in Elderly Patients with NSCLC (ABOUND.70+): Analysis of Safety and Quality of Life (QoL) by CycleE. Kim, Corey J. Langer, J. Weiß et al.|Journal of Thoracic Oncology|2017Cited by 0